Tumors with luminal differentiation—in particular, papillary and micropapillary—demonstrate a high frequency of HER2 overexpression, whereas basal tumors (urothelial carcinomas with squamous differentiation and sarcomatoid carcinomas) rarely express HER2. Here, ERBB2 is linked to urothelial carcinoma.